VR
Verano Holdings Corp.
VRNOF · OTC
$1.30 +8.33% (+$0.10)
Market Cap $470.4M
P/E Ratio -
Div. Yield -
ROE 30.25%
Bulios Fair Price
$1.51
16.2% upside
Current Price
$1.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VRNOF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
98 /100
Cheap P/B 0.24x
P/FCF 12.89x
P/S 0.47x
Growth
100 /100
Growing Rev. growth 117.34%
FCF growth N/A
Book val. growth N/A
Profitability
29 /100
Weak Net margin 36.07%
Op. margin 23.86%
FCF margin 3.67%
Quality
6 /100
Poor ROE 30.25%
ROA 18.65%
Asset turnover 0.52x
Debt
80 /100
Low Current ratio 2.69x
Int. coverage -3.70x
Net debt/EBITDA -0.33x
Stability
6 /100
Unstable Rev. volatility 111.04%
EPS volatility 2,132.99%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VRNOF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
George P. Archos
Employees
3,800
Headquarters
Chicago